Gene therapy watch: 21 patients tracked for years after single treatment

NCT ID NCT06103487

ENROLLING_BY_INVITATION Disease control Sponsor: REGENXBIO Inc. Source: ClinicalTrials.gov ↗

First seen May 04, 2026 · Last updated May 15, 2026 · Updated 1 time

Summary

This study follows 21 people with MPS I who already received RGX-111 gene therapy in an earlier trial. Researchers will monitor them for years to check for side effects and see if the treatment helps with thinking, learning, and daily skills. The goal is to understand the long-term safety and benefits of this one-time gene therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUCOPOLYSACCHARIDOSIS I are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital of Orange County

    Orange, California, 92868, United States

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

Conditions

Explore the condition pages connected to this study.